Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Convertible Debt (2016 - 2018)

Viking Therapeutics' Convertible Debt history spans 4 years, with the latest figure at $1.5 million for Q2 2017.

  • For Q2 2017, Convertible Debt changed 0.0% year-over-year to $1.5 million; the TTM value through Jun 2017 reached $1.5 million, changed 0.0%, while the annual FY2016 figure was $1.5 million, 30.28% down from the prior year.
  • Convertible Debt for Q2 2017 was $1.5 million at Viking Therapeutics, down from $3.7 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $3.7 million in Q1 2017 and bottomed at $1.3 million in Q4 2014.
  • The 4-year median for Convertible Debt is $1.5 million (2016), against an average of $2.0 million.
  • The largest YoY upside for Convertible Debt was 119.57% in 2016 against a maximum downside of 30.28% in 2016.
  • A 4-year view of Convertible Debt shows it stood at $1.3 million in 2014, then soared by 70.2% to $2.2 million in 2015, then tumbled by 30.28% to $1.5 million in 2016, then changed by 0.0% to $1.5 million in 2017.
  • Per Business Quant, the three most recent readings for VKTX's Convertible Debt are $1.5 million (Q2 2017), $3.7 million (Q1 2017), and $1.5 million (Q4 2016).